{"disease":{"id":"hypomethylating-agent","name":"hypomethylating agent"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05841771","title":"Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06465953","title":"Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT04999943","title":"Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Affiliated Hospital to Academy of Military Medical Sciences","has_results":false},{"nct_id":"NCT04454580","title":"Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy","phase":"","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Ospedale Maggiore Di Trieste","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}